FBIO Stock Summary and Trading Ideas (Fortress Biotech | NASDAQ:FBIO)

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

Fortress Biotech trades on the NASDAQ stock market under the symbol FBIO.

As of September 4, 2026, FBIO stock price climbed to $2.72 with 163,213 million shares trading.

FBIO has a beta of 0.01, meaning it tends to be less sensitive to market movements. FBIO has a correlation of 0.00 to the broad based SPY ETF.

FBIO has a market cap of $90.71 million. This is considered a Micro Cap stock.

Last quarter Fortress Biotech reported $19 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $418,000 and exceeded earnings estimates by $.12.

In the last 3 years, FBIO traded as high as $6.15 and as low as $1.24.

The top ETF exchange traded funds that FBIO belongs to (by Net Assets): VTI, VXF, BSVO, AVSC.

FBIO has underperformed the market in the last year with a price return of -4.2% while the SPY ETF gained +19.8%. FBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.8% and -5.2%, respectively, while the SPY returned +2.0% and +0.6%, respectively.

FBIO support price is $2.60 and resistance is $2.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FBIO shares will trade within this expected range on the day.